Efficacy and Safety Analysis of Alfacalcidol Combined with Cinacalcet in the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Renal Failure in Maintenance Hemodialysis
Department of Nephrology, Zhuji People’s Hospital, 1Traditional Chinese Medicine Hospital of Zhuji, Zhuji, Zhejiang 311800, China
Xiafang Zheng, Traditional Chinese Medicine Hospital of Zhuji, Zhuji, Zhejiang 311800, China, E-mail: email@example.com
To investigate the efficacy of alfacalcidol combined with cinacalcet as treatment on secondary hyperparathyroidism in patients with chronic renal failure who are currently in maintenance hemodialysis. Patients in maintenance hemodialysis with chronic renal failure in Zhuji People’s Hospital were selected as the research subjects and randomly divided into the control group and the observation group, 50 cases in each. The patients in the control group were treated with alfacalcidol capsules and the patients in the observation group were treated with alfacalcidol capsules combined with cinacalcet tablets. Both groups were treated for 3 consecutive mo. The clinical efficacy, serum factors (calcium, phosphorus, intact parathyroid hormone, alkaline phosphatase, beta-type I collagen C-terminal peptide and procollagen type I N-terminal propeptide) levels, quality of life, parathyroid volume and Ki-67 protein positive rate were compared between the two groups after treatment. After 3 mo of treatment, the total effective rate (94 %) of the observation group was significantly higher than that of the control group (74 %) and the difference between the two groups was statistically significant (p<0.05). Compared with the control group, the levels of serum factor indexes in the experimental group were improved after treatment and the difference was statistically significant (p<0.05). The parathyroid volume of the patients in the two groups decreased and the experimental group was significantly lower than the control group after treatment (p<0.05). Further research found that the positive rate of Ki-67 protein in the experimental group was significantly lower than that before treatment and the control group after treatment (p<0.05). This combination of medication could improve the efficacy on different aspects like reduce the volume of parathyroid glands, optimize the quality of life of patients and improve the safety of treatment.